PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLornoxicam
Lornoxicam
Lornoxicam is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
ctx3 rinseOTC monograph final2022-12-31
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
M01: Antiinflammatory and antirheumatic products
M01A: Antiinflammatory and antirheumatic products, non-steroids
M01AC: Oxicams, antiinflammatory and antirheumatic drugs
M01AC05: Lornoxicam
HCPCS
No data
Clinical
Clinical Trials
5574 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5017512
Multiple myelomaD009101C90.01214
Plasma cell neoplasmsD0542191214
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.9345
AdenocarcinomaD000230134
CarcinomaD002277C80.0314
NeoplasmsD009369C80323
MelanomaD0085451113
Pancreatic neoplasmsD010190EFO_0003860C2533
LeukemiaD007938C95213
Non-hodgkin lymphomaD008228C85.9223
Large b-cell lymphoma diffuseD016403C83.3223
Ovarian neoplasmsD010051EFO_0003893C56122
Show 23 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lymphoid leukemiaD007945C9122
Squamous cell carcinomaD00229422
Skin neoplasmsD012878EFO_0004198C4411
B-cell chronic lymphocytic leukemiaD015451C91.111
Follicular lymphomaD008224C8211
Interdigitating dendritic cell sarcomaD054739C96.411
Squamous cell neoplasmsD01830711
Adenosquamous carcinomaD01819611
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.011
Philadelphia chromosomeD01067711
Show 8 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLornoxicam
INNlornoxicam
Description
Lornoxicam, also known as chlortenoxicam, is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic (pain relieving), anti-inflammatory and antipyretic (fever reducing) properties. It is available in oral and parenteral formulations.
Classification
Small molecule
Drug classanti-inflammatory agents (isoxicam type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Identifiers
PDB
CAS-ID70374-39-9
RxCUI
ChEMBL IDCHEMBL1569487
ChEBI ID31783
PubChem CID5282204
DrugBankDB06725
UNII IDER09126G7A (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 53,289 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
267 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use